Follicular Lymphoma - Pipeline Insight, 2025

This “Follicular Lymphoma - Pipeline Insight, 2025” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Follicular Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Follicular Lymphoma: Understanding

Follicular Lymphoma: Overview

Follicular lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma (NHL) that arises from B lymphocytes, a type of white blood cell integral to the immune system. It is characterized by the formation of abnormal lymphoid follicles in lymph nodes and other lymphatic tissues. Accounting for about 20% of all NHL cases, FL typically presents with painless lymphadenopathy, often accompanied by symptoms like fatigue, night sweats, or unintentional weight loss in advanced stages. While generally considered indolent, FL can transform into a more aggressive form of lymphoma, necessitating vigilant monitoring. Advances in treatment, including immunotherapy and targeted therapies, have significantly improved outcomes for patients with this condition.

Common symptoms of FL include painless, swollen lymph nodes, often in the neck, armpits, or groin. Other common signs and symptoms include fatigue, unexplained weight loss, night sweats, and fever. Some individuals may also experience a feeling of fullness or discomfort in the abdomen due to an enlarged spleen or liver. Follicular lymphoma arises from the malignant transformation of B lymphocytes, a type of white blood cell, within the germinal centers of lymph nodes. The hallmark of its pathophysiology is the translocation of the BCL2 gene to the immunoglobulin heavy chain locus, most commonly t(14;18)(q32;q21), which leads to overexpression of the BCL2 protein. This protein prevents programmed cell death (apoptosis), allowing the abnormal B cells to survive longer than they should. As these cells accumulate, they form the characteristic follicular or nodular pattern seen in lymph nodes. This resistance to apoptosis, combined with the ability to evade the immune system, contributes to the indolent yet persistent nature of the disease.

The management of FL depends on the disease stage. Options available for the treatment of follicular lymphoma include radiation (RT), immunochemotherapy (Rituximab plus chemotherapy), Bundamustine with immunotherapy, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), immunochemotherapy plus RT, CVP (cyclophosphamide, vincristine, and prednisolone), single-agent rituximab, and observation until progression. The choice of regimen depends on the stage of the disease, preference of physician, and preference of the patient. 

'Follicular Lymphoma- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Follicular Lymphoma pipeline landscape is provided which includes the disease overview and Follicular Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Follicular Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Follicular Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Follicular Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Follicular Lymphoma.

Follicular Lymphoma Emerging Drugs Chapters

This segment of the Follicular Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Follicular Lymphoma Emerging Drugs

MIL62: MAB WORKS

MIL62 is a third-generation anti-CD20 antibody with a unique competitive position. MIL62 is the first domestically developed third-generation anti-CD20 antibody entering Phase III registration trial in China.

MIL62 is self-developed by leveraging our ADCC-enhanced antibody platform. In in vitro and in vivo studies, MIL62 demonstrates stronger ADCC and anti-tumor activities than rituximab (first-generation anti-CD20 antibodies) and obinutuzumab (other third-generation anti-CD20 antibody). The company is implementing critical clinical development strategies to first pursue marketing approval from the NMPA for the treatment of relapsed and/or refractory FL patients and DLBCL patients. At the same time, MIL62 is being developed for previously untreated FL and DLBCL patients (a significantly larger patient population) by demonstrating clinical superiority over rituximab.

AZD0486: AstraZeneca

AZD0486, also known as TNB-486, is an innovative bispecific antibody targeting CD19 and CD3, designed to enhance T-cell-mediated destruction of malignant B cells, particularly in patients with relapsed or refractory follicular lymphoma (FL). AZD0486 functions by engaging T-cells to attack B-cell malignancies, thereby circumventing some limitations associated with traditional therapies. Its design incorporates a low-affinity anti-CD3 moiety, which helps mitigate severe cytokine release syndrome (CRS), a common side effect of T-cell engagers. This unique feature allows for a more controlled immune response, potentially leading to better safety profiles. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Follicular Lymphoma.

Abexinostat: Xynomic Pharmaceuticals

Abexinostat is an oral histone deacetylase (HDAC) inhibitor currently under investigation for the treatment of relapsed or refractory follicular lymphoma (FL). As a pan-HDAC inhibitor, abexinostat alters the transcription of oncogenes and tumor suppressor genes, leading to the inhibition of cancer cell growth. Currently, the drug is in the Phase II stage of development to treat Follicular Lymphoma.

ABBV-319: AbbVie

ABBV-319 is a CD19-targeting antibody-drug conjugate engineered to reduce glucocorticoid-associated toxicities while possessing 3 distinct mechanisms of action (MOA) to increase therapeutic efficacy: (1) antibody-mediated delivery of a glucocorticoid receptor modulator (GRM) payload to activate apoptosis, (2) inhibition of CD19 signaling, and (3) enhanced fragment crystallizable (Fc)-mediated effector function via afucosylation of the antibody backbone. Currently, the drug is in the Phase I stage of development to treat Follicular Lymphoma.

NX-2127: Nurix Therapeutics, Inc.

NX-2127 is an oral, first-in-class, dual-function small molecule degrader that combines BTK degradation with the immunomodulatory activity of an Ikaros and Aiolos degrader. Currently, the drug is in the Phase I stage of development to treat Follicular Lymphoma.

Follicular Lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different Follicular Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Follicular Lymphoma

• There are approx. 45+ key companies which are developing the therapies for Follicular Lymphoma. The companies which have their Follicular Lymphoma drug candidates in the most advanced stage, i.e. Phase III include, MAB WORKS and AstraZeneca.

Phases

The report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Follicular Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Follicular Lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Follicular Lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Follicular Lymphoma drugs.

Follicular Lymphoma Report Insights

• Follicular Lymphoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Follicular Lymphoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Follicular Lymphoma drugs?
• How many Follicular Lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Follicular Lymphoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Follicular Lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Follicular Lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Mab Works
• AstraZeneca
• ADC Therapeutics
• Xynomic Pharmaceuticals
• AbbVie
• Nurix
• InnoCare Pharma
• LTZ Therapeutics
• Hutchmed
• Regeneron Pharmaceuticals
• Pfizer
• InnoCare Pharma
• TriSalus Life Sciences
• BeiGene

Key Products

• MIL62
• AZD0486
• Acalabrutinib
• Loncastuximab tesirine
• Abexinostat
• ABBV-319
• NX-2127
• ICP 248
• LTZ-301
• HMPL-689
• Odronextamab
• PF-06821497
• ICP-248
• Nelitolimod
• Zanubrutinib

This product will be delivered within 1-3 business days.